A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
Trial details
- Registry ID
- NCT04112199
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as terlipressin diacetate
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory AscitesNCT04112199 | BIVI | Phase 2 | Terminated | 2023-05-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |